Travere Therapeutics, Inc. (TVTX)

In the past six months, Travere Therapeutics' stock has experienced significant movements, surging approximately 107% since a "Buy" rating due to FILSPARI's performance and approvals. In August 2025, the FDA eased REMS monitoring requirements for FILSPARI. In October 2025, the company reported strong financial results for Q3 2025, with earnings per share of $0.59 and revenue reaching $164.9 million, and received a $40 million milestone payment from CSL Vifor. In January 2026, preliminary Q4 2025 U.S. net product sales were announced at approximately $127 million, with FILSPARI contributing about $103 million. On January 13, 2026, the stock declined by 14.63% to 31.7% after the FDA extended its review timeline for FILSPARI in FSGS. There has been notable insider selling activity over the past three months, with insiders selling over $11 million in company stock.

Information regarding specific demand seasonality for Travere Therapeutics' products and services is not explicitly available. Demand for pharmaceutical products is generally driven by disease prevalence, diagnosis rates, and treatment access rather than typical seasonal patterns. The company's reports focus on overall sales growth and new patient starts, indicating a consistent demand based on medical need rather than seasonal fluctuations.

Travere Therapeutics, Inc. is a biopharmaceutical company focused on identifying, developing, and delivering therapies for individuals with rare kidney and metabolic diseases. The company operates in the Healthcare sector, specifically in the Biotechnology industry, with a therapeutic focus on IgA Nephropathy (IgAN), Focal Segmental Glomerulosclerosis (FSGS), Classical Homocystinuria (HCU), and Cystinuria. Its major commercial products include FILSPARI (sparsentan), indicated for IgAN and in late-stage development for FSGS, Thiola and Thiola EC (tiopronin tablets) for cystinuria, and Chenodal and Cholbam. The company's pipeline also includes Pegtibatinase (TVT-058) for classical homocystinuria (HCU).

Travere Therapeutics is headquartered in San Diego, California, United States, and has a global reach through commercial partnerships. CSL Vifor holds exclusive commercial rights for sparsentan in Europe, Australia, New Zealand, Bahrain, Brazil, Chile, Israel, Kuwait, Oman, Qatar, Saudi Arabia, and the United Arab Emirates. Chugai Pharmaceutical Co. has exclusive rights to develop and commercialize sparsentan in Japan, South Korea, and Taiwan. The company also has associated legal entities and subsidiaries in Ireland, the Netherlands, and Switzerland.

In the past year, Travere Therapeutics' brand reputation has been influenced by both positive developments and challenges. The company has generally received a "Moderate Buy" consensus rating from analysts, with an average target price of $38.71. FILSPARI's strong commercial performance and approvals, along with positive financial results and pipeline advancement, have contributed positively to its reputation. However, the FDA review delay for FILSPARI in FSGS, insider selling activity, and financial health concerns have negatively impacted its reputation.

The ownership structure of Travere Therapeutics (TVTX) stock is primarily institutional, with institutional investors holding approximately 69.68% to 88.4% of the company's stock. Major institutional owners include Janus Henderson Group Plc, BlackRock, Inc., and Armistice Capital, Llc. Individual (insider) ownership is relatively low, ranging from 1.51% to 4.64%. Ruth Shepley is identified as the largest individual shareholder, owning 49 million shares, representing 54.77% of the company.